TP53 and myelodysplastic syndrome: A multicenter, phase 2, open label study evaluating APR-246, a novel p53 reactivator, in combination with azacitidine for TP53 mutated AML or MDS post alloBMT is nearly complete with results anticipated in the coming year (NCT03931291) (84).